Use este identificador para citar ou linkar para este item: https://repositorio.inpa.gov.br/handle/1/16094
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSilva, Luiz Francisco Rocha e-
dc.contributor.authorMontoia, Andréia-
dc.contributor.authorAmorim, Rodrigo C.N.-
dc.contributor.authorMelo, Márcia R.S.-
dc.contributor.authorHenrique, Marycleuma Campos-
dc.contributor.authorNunomura, Sergio Massayoshi-
dc.contributor.authorCosta, Mônica Regina Farias-
dc.contributor.authorAndrade Neto, Valter Ferreira de-
dc.contributor.authorCosta, David Siqueira-
dc.contributor.authorDantas, Glucia L.S.-
dc.contributor.authorLavrado, João-
dc.contributor.authorMoreira, Rui R.N.-
dc.contributor.authorPaulo, Alexandra-
dc.contributor.authorPinto, A. C.-
dc.contributor.authorTadei, Wanderli Pedro-
dc.contributor.authorZacardi, R. S.-
dc.contributor.authorEberlin, M. N.-
dc.contributor.authorPohlit, Adrian Martin-
dc.date.accessioned2020-05-24T21:19:36Z-
dc.date.available2020-05-24T21:19:36Z-
dc.date.issued2012-
dc.identifier.urihttps://repositorio.inpa.gov.br/handle/1/16094-
dc.description.abstractIndole alkaloids ellipticine (1), cryptolepine triflate (2a), rationally designed 11-(4-piperidinamino)cryptolepine hydrogen dichloride (2b) and olivacine (3) (an isomer of 1) were evaluated in vitro against Plasmodium falciparum and in vivo in Plasmodium berghei-infected mice. 1-3 inhibited P. falciparum (IC50 ≤ 1.4 μM, order of activity: 2b > 1 > 2a > 3). In vitro toxicity to murine macrophages was evaluated and revealed selectivity indices (SI) of 10-12 for 2a and SI > 2.8 × 102 for 1, 2b and 3. 1 administered orally at 50 mg/kg/day was highly active against P. berghei (in vivo inhibition compared to untreated control (IVI) = 100%, mean survival time (MST) > 40 days, comparable activity to chloroquine control). 1 administered orally and subcutaneously was active at 10 mg/kg/day (IVI = 70-77%; MST = 27-29 days). 3 exhibited high oral activity at ≥50 mg/kg/day (IVI = 90-97%, MST = 23-27 days). Cryptolepine (2a) administered orally and subcutaneously exhibited moderate activity at 50 mg/kg/day (IVI = 43-63%, MST = 24-25 days). At 50 mg/kg/day, 2b administered subcutaneously was lethal to infected mice (MST = 3 days) and moderately active when administered orally (IVI = 45-55%, MST = 25 days). 1 and 3 are promising compounds for development of antimalarials. © 2012 Elsevier GmbH.en
dc.language.isoenpt_BR
dc.relation.ispartofVolume 20, Número 1, Pags. 71-76pt_BR
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Brazil*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/br/*
dc.subjectCryptolepine Derivativeen
dc.subjectCryptolepine Triflateen
dc.subjectEllipticineen
dc.subjectOlivacineen
dc.subjectUnclassified Drugen
dc.subjectAnimals Experimenten
dc.subjectAntimalarial Activityen
dc.subjectControlled Studyen
dc.subjectDrug Cytotoxicityen
dc.subjectIc 50en
dc.subjectIn Vitro Studyen
dc.subjectIn Vivo Studyen
dc.subjectLethal Doseen
dc.subjectMouseen
dc.subjectNonhumanen
dc.subjectPlasmodiumen
dc.subjectPlasmodium Bergheien
dc.subjectPriority Journalen
dc.subjectSurvival Timeen
dc.subjectAnimalen
dc.subjectAntimalarialsen
dc.subjectAspidospermaen
dc.subjectEllipticinesen
dc.subjectFemaleen
dc.subjectIndole Alkaloidsen
dc.subjectMacrophagesen
dc.subjectMalariaen
dc.subjectMiceen
dc.subjectMice, Inbred Strainsen
dc.subjectPhytotherapyen
dc.subjectPlant Extractsen
dc.subjectPlasmodium Bergheien
dc.subjectPlasmodium Falciparumen
dc.subjectQuinolinesen
dc.subjectMurinaeen
dc.subjectMusen
dc.subjectPlasmodium Bergheien
dc.subjectPlasmodium Falciparumen
dc.titleComparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analogen
dc.typeArtigopt_BR
dc.identifier.doi10.1016/j.phymed.2012.09.008-
dc.publisher.journalPhytomedicinept_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
artigo-inpa.pdf325,9 kBAdobe PDFThumbnail
Visualizar/Abrir


Este item está licenciada sob uma Licença Creative Commons Creative Commons